In addition, since BMAL1 expression exhibits a stable circadian rhythm in healthy individuals and in cancer cells, BMAL1 could serve as a direct molecular target for PTX to determine the best drug administration time for personalized chronotherapies (Tang et al., 2017) and may contribute to improving the efficacy of anticancer drugs and reduce their toxicity. This evidence concerns the gene BMAL1 and cancer.